Cross-Species Organ Transplantation Market Report 2026

The cross-species organ transplantation market size has grown strongly in recent years. It will grow from $15.2 billion in 2025 to $16.5 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to shortage of human donor organs, early-stage xenotransplant research initiatives, advancements in genetic engineering tools, preclinical validation of animal-derived organs, increasing transplant waiting lists.

The cross-species organ transplantation market size is expected to see strong growth in the next few years. It will grow to $22.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing clinical trial activity in xenotransplantation, rising investment in gene-edited animal models, growing collaboration between biotech firms and transplant centers, advancements in immunosuppressive therapies, expanding regulatory frameworks for xenotransplants. Major trends in the forecast period include increasing advancements in genetically engineered donor organs, growing focus on immune rejection mitigation strategies, expansion of organ preservation and perfusion technologies, rising investment in translational xenotransplant research, enhanced regulatory and ethical oversight.

The growing shift towards genetic engineering is expected to propel the growth of the cross-species organ transplantation market going forward. Genetic engineering refers to the deliberate modification of an organism’s DNA using biotechnology techniques to introduce, remove, or alter specific genes. The rise in genetic engineering is due to the urgent need to address organ shortages by creating animal organs that are more compatible for human transplantation. Genetic engineering supports the growth of cross-species organ transplantation by enabling the modification of animal organs to reduce immune rejection, making them suitable for human transplants. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, there were 247 gene therapies in Phase II by the end of first quarter of 2023, increasing by 5% to reach 260 by the end of the second quarter. Therefore, the growing shift towards genetic engineering is driving the growth of the cross-species organ transplantation market.

Major companies operating in the cross-species organ transplantation market are focusing on adopting strategic partnerships to streamline the regulatory approval process for xenotransplantation solutions. A strategic partnership is an alliance where companies work together to achieve common goals by utilizing each other’s strengths and resources, aiming to boost growth, innovation, and competitiveness without merging. For instance, in February 2025, United Therapeutics, a US-based biotechnology company, and eGenesis, a US-based pharmaceutical company to begin clinical trials for pig kidney (xenotransplant) transplants in humans. This trial received approval from the U.S. Food and Drug Administration (FDA) to transplant genetically modified pig kidneys into patients with kidney failure. The trials aim to address the critical shortage of donor kidneys by potentially providing a new, sustainable organ source for those in need.

In December 2023, United Therapeutics Corporation, a US-based biotechnology company that provides xenotransplantation solutions, acquired Miromatrix Medical Inc. for an undisclosed amount. With this acquisition, United Therapeutics Corporation expanded its capabilities in developing bioengineered organs for transplantation, particularly in advancing its cross-species (xenotransplantation) initiatives. Miromatrix Medical Inc. is a US-based company that provides bioengineered organs derived through decellularization and recellularization techniques.

Major companies operating in the cross-species organ transplantation market are Novartis AG, Optipharm Co Ltd, Astellas Pharma Inc., United Therapeutics Corporation, TransMedics Group Inc., Artivion Inc., eGenesis Inc., Organ Recovery Systems Inc., OrganOX Ltd, Paragonix Technologies Inc., Qihan Biotech, PorMedTec Co., XenoTheraputics Inc., Makana Therapeutics Inc., Preservation Solutions Inc., Nzeno Ltd, Infigen Inc., Revivicor Inc., XVIVO Perfusion AB, Bridge To Life Ltd, Transplant Genomics Inc.

North America was the largest region in the cross-species organ transplantation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cross-species organ transplantation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cross-species organ transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cross-species organ transplantation market by increasing costs of imported genetic engineering tools, laboratory equipment, bioprocessing materials, and specialized organ preservation devices. Research institutions and biotech companies in North America and Europe are most affected due to dependence on imported high-end biomedical equipment, while Asia-Pacific faces higher costs for research-scale manufacturing. These tariffs are increasing development expenses and extending research timelines. However, they are also encouraging domestic biotechnology manufacturing, localized research infrastructure development, and regional innovation ecosystems supporting xenotransplantation.

The cross-species organ transplantation market research report is one of a series of new reports that provides cross-species organ transplantation market statistics, including cross-species organ transplantation industry global market size, regional shares, competitors with a cross-species organ transplantation market share, detailed cross-species organ transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the cross-species organ transplantation industry. This cross-species organ transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cross-species organ transplantation, also known as xenotransplantation, is the transplantation of living cells, tissues, or whole organs from one species into a different species, typically from animals to humans. The primary goal of xenotransplantation is to address the shortage of human donor organs for patients in need of transplants.

The main product types of cross-species organ transplantation are organ preservation solution, transplant diagnostics, xeno products, and others. Organ preservation solution is a specially formulated liquid used to keep organs viable outside the body during transportation and before transplantation. It is applied in various applications, including kidney, heart, liver, lung, and others, and is used by several end users, including transplant centers, hospitals, and others.

The cross-species organ transplantation market consists of revenues earned by entities by providing services such as preclinical and clinical xenotransplantation services, organ and tissue matching, post-transplant care and monitoring, and regenerative and bioengineered solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The cross-species organ transplantation market also includes sales of immunosuppressive drugs, bioengineered tissues, and organ scaffolds or matrices. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.